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Objective: To develop evidence based recommendations for the management of ankylosing spondylitis
(AS) as a combined effort of the ‘ASsessment in AS’ international working group and the European League
Against Rheumatism.
Methods: Each of the 22 participants was asked to contribute up to 15 propositions describing key clinical
aspects of AS management. A Delphi process was used to select 10 final propositions. A systematic
literature search was then performed to obtain scientific evidence for each proposition. Outcome data for
efficacy, adverse effects, and cost effectiveness were abstracted. The effect size, relative risk, number
needed to treat, and incremental cost effectiveness ratio were calculated. On the basis of the search results,
10 major recommendations for the management of AS were constructed. The strength of recommendation
was assessed based on the strength of the literature evidence, risk-benefit trade-off, and clinical expertise.
Results: The final recommendations considered the use of non-steroidal anti-inflammatory drugs (NSAIDs)
(conventional NSAIDs, coxibs, and co-prescription of gastroprotective agents), disease modifying
antirheumatic drugs, treatments with biological agents, simple analgesics, local and systemic steroids,
non-pharmacological treatment (including education, exercise, and physiotherapy), and surgical
interventions. Three general recommendations were also included. Research evidence (categories I–IV)
supported 11 interventions in the treatment of AS. Strength of recommendation varied, depending on the
category of evidence and expert opinion.
Conclusion: Ten key recommendations for the treatment of AS were developed and assessed using a
combination of research based evidence and expert consensus. Regular updating will be carried out to
keep abreast of new developments in the management of AS.
A
nkylosing spondylitis (AS) is a chronic, inflammatory
rheumatic disease characterised by inflammatory back
pain due to sacroiliitis and spondylitis, the formation of
syndesmophytes leading to ankylosis, and frequently asso-
ciated with peripheral arthritis, enthesitis, and acute anterior
uveitis. Symptoms commonly begin in late adolescence and
early adulthood.1 2 With an estimated prevalence of 0.9% in
northern European white populations3 AS is a significant
health burden to the community.
AS has long been a therapeutic challenge for the clinician.
Exercise and non-steroidal anti-inflammatory drugs
(NSAIDs) have been the mainstay of symptom control for
decades, but there has until recently been a dearth of disease
modifying treatments. The advent of biological treatment is
currently revolutionising the management of AS, but too
little is known yet about the long term benefits and risks of
such treatment. Clearly, these treatments necessitate socio-
economic cost calculations. Moreover, there is a need for
rational, evidence based recommendations to guide the
physician in the management of AS. The ASsessment in AS
(ASAS) international working group has made important
contributions to the evaluation and standardisation of
assessments in AS in the past decade.4 5
This project is a collaborative effort of ASAS and EULAR
with the ultimate objective to contribute to the improvement
of outcomes in patients with AS by constructing evidence
based management recommendations. To obtain and main-
tain a high level of intrinsic quality and comparability of this
approach, the EULAR standard operating procedures6 were
followed.
METHODS
Participants
A multidisciplinary guideline development committee was
formed from within the ASAS working group, with partici-
pants selected on the basis of publication history in AS,
personal knowledge, and approval by EULAR. Twenty two
experts in the field of AS (20 rheumatologists, one also a
patient with AS, and two orthopaedic surgeons) representing
14 countries took part in the study. Each participant was
asked to contribute independently up to 15 key propositions
relevant to the management of AS, to create a comprehensive
list of potential topics of interest. A Delphi technique was
then used to reduce these to a predefined final 10
propositions over three rounds. Questions were accepted
automatically if selected by 80% or more of the participants in
any round, whereas questions receiving less than 20% of the
votes were removed.
Abbreviations: AS, ankylosing spondylitis; ASAS, ASsessment in AS;
CI, confidence interval; DMARDs, disease modifying antirheumatic
drugs; ES, effect size; MRI, magnetic resonance imaging; NRS,
numerical rating scale; NSAIDs, non-steroidal anti-inflammatory drugs;
OA, osteoarthritis; RCT, randomised controlled trial; THA, total hip
arthroplasty; TNF, tumour necrosis factor; VAS, visual analogue scale
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Systematic literature search
A general search of Medline, Embase, CINHAL, PEDro, and
the Cochrane Library was conducted summarising the
current available AS treatments from the literature, and the
results reported to the committee before the Delphi exercise.
After the 10 propositions had been generated, an interven-
tion-specific literature search was undertaken to identify
evidence for each specified intervention.7 The ‘‘online first’’
sections of rheumatology journals as well as the abstracts of
rheumatology scientific meetings from the years 2003 and
2004 were hand searched for additional relevant studies.
Only studies with clinical outcomes for AS were included.
Animal studies, narrative review articles, commentaries, and
guidelines were excluded.
Categorising evidence
Evidence was categorised according to study design using a
traditional hierarchy8 (table 1). Questions on efficacy were
Table 1 Evidence hierarchy and traditional strength of recommendation
Category of evidence Strength of recommendation
Ia Meta-analysis of randomised controlled trials A Category I evidence
Ib Randomised controlled trial
IIa Controlled study without randomisation B Category II evidence or extrapolated from category I
evidence
IIb Quasi-experimental study
III Non-experimental descriptive studies, such as
comparative, correlation, and case-control studies
C Category III evidence or extrapolated from category I
or II evidence
IV Expert committee reports or opinion or clinical
experience of respected authorities, or both
D Category IV evidence or extrapolated from category II
or III evidence
Table 2 Experts’ propositions developed through three Delphi rounds—order according
to topic (general, non-pharmacological, pharmacological, invasive, and surgical)
No Proposition
1 Treatment of AS should be tailored according to:
l Current manifestations of the disease (axial, peripheral, entheseal, extra-articular symptoms and signs)
l Level of current symptoms, clinical findings, and prognostic indicators
- Disease activity/inflammation
- Pain
- Function, disability, handicap
- Structural damage, hip involvement, spinal deformities
l General clinical status (age, sex, comorbidity, concomitant drugs)
l Wishes and expectations of the patient
2 Disease monitoring of patients with AS should include: patient history (for example, questionnaires),
clinical parameters, laboratory tests, and imaging, all according to the clinical presentation, as well as the
ASAS core set. The frequency of monitoring should be decided on an individual basis depending on
symptoms, severity, and drug treatment
3 Optimal management of AS requires a combination of non-pharmacological and pharmacological
treatments
4 Non-pharmacological treatment of AS should include patient education and regular exercise. Individual
and group physical therapy should be considered. Patient associations and self help groups may be useful
5 NSAIDs are recommended as first line drug treatment for patients with AS with pain and stiffness. In those
with increased GI risk, non-selective NSAIDs plus a gastroprotective agent, or a selective COX-2 inhibitor
could be used
6 Analgesics, such as paracetamol and opioids, might be considered for pain control in patients in whom
NSAIDs are insufficient, contraindicated, and/or poorly tolerated
7 Corticosteroid injections directed to the local site of musculoskeletal inflammation may be considered. The
use of systemic corticosteroids for axial disease is not supported by evidence
8 There is no evidence for the efficacy of DMARDs, including sulfasalazine and methotrexate, for the
treatment of axial disease. Sulfasalazine may be considered in patients with peripheral arthritis
9 Anti-TNF treatment should be given to patients with persistently high disease activity despite conventional
treatments according to the ASAS recommendations. There is no evidence to support the obligatory use of
DMARDs before, or concomitant with, anti-TNF treatment in patients with axial disease
10 Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic
evidence of structural damage, independent of age. Spinal surgery—for example, corrective osteotomy
and stabilisation procedures, may be of value in selected patients
AS, ankylosing spondylitis; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; DMARDs, disease
modifying antirheumatic drugs; TNF, tumour necrosis factor.
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answered using the ‘‘best available’’ evidence. The highest
available category of evidence for each intervention was
reviewed in depth, and the next highest category considered
when few high level studies were retrieved. Whereas efficacy
was assessed specifically for AS, side effects were evaluated
specifically for the intervention, and so studies in other
musculoskeletal diseases were also reviewed.
Estimation of effectiveness and cost effectiveness
Effect size (ES) and 95% confidence interval (95% CI) for
each intervention were calculated for two predefined
continuous outcomes: pain relief and improvement in
function.9 ES is the standardised mean difference (mean
change divided by standard deviation of the change), and
therefore has no units and is comparable across interventions
in similar populations. Clinically, an ES of 0.2 is considered
small, 0.5 is moderate, and .0.8 is large.10 Statistical pooling
was undertaken as appropriate.11 The percentage of patients
responding to treatment (an ASAS20 response, pain relief of
more than 50%, or functional improvement of more than
20%) was calculated where possible, and the number needed
to treat (the number of patients who need to be treated to
prevent one additional poor outcome) was estimated.12
Relative risk was calculated for adverse effects.
For economic evaluations, the incremental cost effective-
ness ratio was calculated. Data were extracted by one
investigator (JZ). A customised form was used for the data
extraction.
Strength of recommendation
The strength of each recommendation was graded A–D based
on the category of efficacy evidence (table 1)8 by two
members of the committee (JZ, JB). A numerical rating scale
(NRS) was used to quantify ‘‘expert opinion’’ for each
intervention identified. Each member of the committee was
asked to rate their strength of recommendation for each
intervention on a 0–10 NRS, according to both the research
evidence presented (efficacy, safety, and cost effectiveness)
and their own clinical expertise (logistics, patient perceived
acceptance, and tolerability). The mean (SEM) for the
strength of the recommendation was calculated for each
intervention.
When the final 10 recommendations had been agreed, a
flow chart was constructed by the expert group to summarise
the most important aspects of the management of AS, based
on clinical expertise and research evidence.
RESULTS
Details of the literature search results and the specific studies
discussed during the elucidation of each recommendation
have been published elsewhere.7 Table 2 gives the final 10
recommendations.
The first three recommendations deal with general
concepts in the management of AS, and the remaining seven
describe specific treatments in use for AS. Tables 3-5
summarise the evidence for efficacy, toxicity, and cost
effectiveness for each intervention. Table 6 gives the strength
of each recommendation as assigned by the expert group.
Table 3 Evidence of efficacy—pooled effect size (ES) and number needed to treat (NNT)
Intervention
Studies
ESpain, spinal
(95% CI)
ESpain, peripheral
(95% CI)
ESfunction
(95% CI)
NNT (95% CI)
(ASAS 20)Category* No
Duration
(weeks)
Physiotherapy Ib 1 16 NS – 1.14 (0.55 to 1.73) –
Home exercise IIa 1 8 1.99 (1.30 to 2.67) – 0.80 (0.23 to 1.38) –
NSAIDs Ib 4 6 1.11 (0.96 to 1.26) 0.62 (0.26 to 0.97) 0.62 (0.47 to 0.76) –
Coxibs Ib 3 6 1.05 (0.88 to 1.22) – 0.63 (0.47 to 0.80) –
Sulfasalazine Ia 6 26–52 NS NS NS –
Methotrexate Ib 2 26–52 NS – NS –
Leflunomide Ib 1 24 NS – NS NS
Etanercept Ib 4 6–24 2.25 (1.92 to 2.59) 0.56 (0.07 to 1.04) 2.11 (1.81 to 2.41) 2.7 (2.2 to 3.4)
Infliximab Ib 2 12–24 0.90 (0.66 to 1.14) 0.66 (0.17 to 1.14) 0.93 (0.69 to 1.17) 2.3 (1.8 to 2.4)
TNFa inhibitors Ib 6 6–24 1.36 (1.16 to 1.55) 0.61 (0.27 to 0.95) 1.39 (1.20 to 1.57) 2.6 (2.2 to 3.0)
*See table 1 for definitions; peripheral joint pain was reported in two etanercept studies and one infliximab study, n (total) = 3
No, number of studies included in pooling data; ES, effect size of treatment compared with placebo unless otherwise stated; NNT, number needed to treat to obtain
ASAS20 response; –, not available; NS, not significant; ASAS20, ankylosing spondylitis assessment definition of clinical response to treatment.
Table 4 Evidence of side effects—pooled relative risk
(RR) and 95% confidence interval (CI) from randomised
controlled trials (RCTs)
Intervention* RR (95% CI)
NSAIDs 5.36 (1.79 to 16.10) GI (serious)
0.86 (0.75 to 0.99) CV
Coxibs v NSAIDs 0.18 (0.14 to 0.23) GI (serious)
0.79 (0.40 to 1.55) CV
Misoprostol 0.26 (0.17 to 0.39) GI (serious)
1.81 (1.52 to 2.61) diarrhoea
H2 blockers (double doses) 0.44 (0.03 to 0.74) GI (serious)
PPIs 0.40 (0.32 to 0.51) GI (serious)
Sulfasalazine 2.37 (1.58 to 3.55) any
1.79 (1.36 to 2.34) GI (any)
1.82 (1.13 to 2.93) mucocutaneous
4.01 (2.12 to 7.59) haematological
1.90 (0.75 to 4.82) hepatic
Methotrexate 2.12 (1.50 to 2.98) nausea
4.12 (2.22 to 7.63) hepatic
2.62 (0.71 to 9.68) haematological
1.31 (0.57 to 3.01) mucocutaneous
1.54 (0.64 to 3.70) alopecia
2.03 (0.55 to 7.50) rash
Folate+MTX v MTX 0.56 (0.38 to 0.80)
Paracetamol 0.80 (0.27 to 2.37) GI
TNF inhibitors 1.07 (0.92 to 1.24) any infection
3.12 (2.50 to 3.90) injection site
2.38 (1.61 to 3.53) ANA
0.81 (0.62 to 1.06) serious AEs
*:Compared with placebo/non-exposure unless otherwise stated. Results
were pooled from RCTs, or obtained from the latest systematic review
which contains the most RCTs.
H2 blockers, histamine type 2 receptor antagonists; PPIs, proton pump
inhibitors; MTX, methotrexate; TNF, tumour necrosis factor; GI,
gastrointestinal; CV, cardiovascular; ANA, antinuclear antibodies; AEs,
adverse effects.
444 Zochling, van der Heijde, Burgos-Vargas, et al
www.annrheumdis.com
 group.bmj.com on April 25, 2013 - Published by ard.bmj.comDownloaded from 
Propositions
1. Treatment of AS should be tailored according to:
N Current manifestations of the disease (axial, peripheral,
entheseal, extra-articular symptoms and signs)
N Level of current symptoms, clinical findings, and prog-
nostic indicators
– Disease activity/inflammation
– Pain
– Function, disability, handicap
– Structural damage, hip involvement, spinal deformities
N General clinical status (age, sex, comorbidity, concomitant
drugs)
N Wishes and expectations of the patient.
This statement represents ideal practice and includes clinical
markers that are often used to guide clinical decisions.
However, although it has considerable face validity, there is
little experimental evidence to support it. Trials to evaluate
treatment efficacy frequently include a highly selected
population. Few studies are therefore designed to differenti-
ate therapeutic effects according to patient characteristics.
General information on these factors can better be obtained
Table 5 Evidence of cost effectiveness for the proposed interventions
Intervention Comparator Perspective Duration Discounting Effectiveness C1–C2 E1–E2 ICER
Group physiotherapy Home exercise Institutional/
payer
1 year No Patients global
health (VAS) cm
$409–0 1.7–0.3 292
Spa exercise therapy Conventional treatment Institutional/
payer
40 weeks No QALYs J3129–1754 – 12869
Education programme Conventional treatment Societal 1 year No Work days lost Saving
Coxib (patients with
OA/RA)
Naproxen 3rd party
payer
Life 3% QALYs $16620–5037 – 395324
Coxib (patients with
OA/RA) (previous GI
haemorrhage)
Naproxen 3rd party
payer
Life 5% QALYs $19015–14294 – 55803
NSAIDs+misoprostol
(all patients with OA)
NSAIDs Canadian
Health services
3 months No GI events
averted
$32396–25622 96–86 684
NSAIDs+misoprostol
(patients with OA aged
>65 years)
NSAIDs Canadian
Health services
3 months No GI events
averted
$28971–25622 91–86 644
Infliximab Conventional treatment Societal 2 years 3% QALYs £25126–17240 0.17–0 6624
C1, total costs with intervention; C2, total costs with comparator; E1, effects with intervention; E2, effects with comparator; ICER, incremental cost effectiveness
ratio, base case scenario; QALYs, quality adjusted life years.
Table 6 Strength of recommendations
Intervention
Research evidence* SOR based on
efficacy (A–D)
SOR based on all
evidence and clinical
expertise NRS, mean
(SEM)
Efficacy Side effects Cost effectiveness
Physiotherapy Ib + – – A 7.95 (0.37)
Exercise IIa + – – B 8.86 (0.27)
Education – – – N/A 8.18 (0.38)
Cognitive therapy – – – N/A 4.77 (0.58)
NSAIDs Ib + Ia + (GI) N/A A 9.14 (0.24)
Coxibs Ib + Ia 2 (GI) Higher GI risk population A 7.82 (0.38)
Misoprostol Ia + (GI protection) Ia + (diarrhoea) Higher GI risk population A 5.55 (0.55)
H2 Blockers (double dose) Ia + (GI protection) – High GI risk population A 5.73 (0.46)
Proton pump inhibitors Ia + (GI protection) – – A 7.14 (0.39)
Sulfasalazine Ia ¡ Ib + (haematological,
mucocutaneous, GI)
– A 6.11 (0.72)
Methotrexate Ib 2 Ib + (nausea, hepatic) – A 3.14 (0.46)
Ciclosporin IV + – – D 1.48 (0.38)
Azathioprine IV + – – D 1.33 (0.33)
Hydroxychloroquine – – – N/A 0.86 (0.30)
Auranofin III 2 – – C 0.57 (0.24)
Cyclophosphamide IV + – – D 0.86 (0.26)
Leflunomide Ib 2 – – A 2.19 (0.39)
D-Penicillamine Ib 2 – – A 0.90 (0.33)
Pamidronate III + III + (acute phase reaction) – C 4.29 (0.38)
Thalidomide III + III + (neurological) – C 3.48 (0.39)
Methylprednisolone (IV) IV + – – D 3.90 (0.45)
Infliximab Ib + Ib + (ANA formation) Cost effective A 9.48 (0.20)
Etanercept Ib + Ib + (injection site reactions) Cost effective A 9.48 (0.20)
Adalimumab III + – – C 7.24 (0.56)
Anakinra III ¡ – – C 3.14 (0.53)
Total hip replacement IV + – – D 9.05 (0.28)
Spinal surgery IV + – – D 7.23 (0.35)
*Evidence was categorised according to the hierarchy in table 1. –, not supportive; +, supportive. ¡, uncertain. Example, Ia + (GI) means there is category Ia
evidence to support the statement that the treatment causes GI side effects.
SOR, strength of recommendation; NRS, numeric rating scale (0–10, 0 = not recommended at all, 10 = fully recommended); GI, gastrointestinal; ANA, antinuclear
antibodies; –, not available; N/A, not applicable.
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from observational studies. For example, in observational
cohorts, hip involvement is the most important and
consistent factor predisposing to severe disease.13 However,
there is no international consensus on disease severity of
patients with AS. Other clinical prognostic indicators include
age, sex, number of peripheral joints affected, smoking,
raised erythrocyte sedimentation rate, poor response to
NSAIDs,13–16 and radiological changes at baseline.17 18
In a recent review, in which the results of two randomised
trials of biological treatment in AS were analysed according
to patient factors,19 the response to anti-tumour necrosis
factor (TNF) treatment was better in younger patients with
shorter disease duration and less functional disability.
However, because both studies were carried out in patients
with high disease activity at baseline, it is not possible to
generalise these conclusions to a wider population of patients
with AS.
2. Disease monitoring of patients with AS should
include: patient history (for example,
questionnaires), clinical parameters, laboratory
tests, and imaging, all according to the clinical
presentation as well as the ASAS core set. The
frequency of monitoring should be decided on an
individual basis depending on symptoms, severity,
and drug treatment
Clinical presentation includes all aspects of disease expres-
sion in AS, including axial disease, peripheral disease,
enthesitis, and extra-articular manifestations (such as acute
uveitis, conjunctivitis, carditis).
The ASAS working group has developed a core set for use
in clinical record keeping.20 21 This core set includes domains
on axial, peripheral, and enthesopathological manifestations,
and for each domain, one or more specific instruments are
recommended (table 7).
Imaging is an evolving science in the evaluation of AS. The
expert group discussed at length what might be the optimal
frequency for radiological evaluation of AS, and it was
concluded that based on the recent modified Stokes AS
Spinal Score data,22 and clinical experience, radiographic
monitoring may not be needed more often than once every
2 years. However, exceptions are possible because syndesmo-
phytes may have developed already within 6 months in some
patients—this is considered to be the smallest interval
between two x ray examinations. Films of the lateral cervical
and lumbar spine are recommended for assessing change
over time. Assessments of the thoracic spine may also be
useful in individual patients, especially where fractures are
suspected. Similarly, an additional anteroposterior (AP)
lumbar spine film may give further information for assessing
disease status in some patients. Once diagnostic changes
have been detected in the sacroiliac joints, sacroiliac x ray
examinations add little information, but periodic radio-
graphic assessment of the hips may be of value.
Recommendations on this item have not been finalised as
yet.
Magnetic resonance imaging (MRI) of the sacroiliac joints
and the spine is increasingly used to assess disease activity in
AS. Although it has not been incorporated in the ASAS core
set to date, it seems likely on the basis of recent data that
MRI will have a role both in clinical trials and in daily care of
the patients, because it is advantageous to have some
objective evidence of spinal inflammation.23–25
3. Optimal management of AS requires a
combination of non-pharmacological and
pharmacological treatments
Over 15% of the studies retrieved from the broad literature
search reported the effects of non-pharmacological treat-
ments in AS. Again, no specific head to head studies have
been performed to compare the effect of pharmacological and
non-pharmacological treatments. The group consensus was
that non-pharmacological and pharmacological treatments
are complementary and both are of value in the initial and
continuing treatment of patients with AS. Whether this
combined approach applies equally to early and advanced
disease or to very active and inactive disease states has not
yet been resolved. Figure 1 shows the recommended
Table 7 ASAS core sets
Domain
Core set
Instruments
CR SMARD/PT DC-ART
Physical function x x x Bath Ankylosing Spondylitis Functional Index (BASFI) or Dougados
Functional Index
Pain x x x VAS in the past week, spine at night, due to AS and VAS in the past
week, spine due to AS
Spinal mobility x x x Chest expansion and modified Schober and occiput to wall distance
and (BASMI or lateral side flexion)
Patient’s global assessment x x x VAS in the past week
Stiffness x x x Morning stiffness
Peripheral joints and entheses x x Number of swollen joints and assessment of painful entheses
Acute phase reactants x x ESR
Fatigue x VAS question on fatigue from BASDAI
Imaging x AP and lateral x ray examination of the lumbar spine, lateral cervical
spine, AP pelvis (SI and hip joints)
CR, clinical record keeping; SMARD, symptom modifying antirheumatic drug; PT, physical therapy; DC-ART, disease controlling antirheumatic treatment; VAS,
visual analogue scale; BASMI, Bath Ankylosing Spondylitis metrology Index; ESR, erythrocyte sedimentation rate; AP, anteroposterior; SI, sacroiliac.
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Figure 1 Flow chart summary of the recommended management of AS,
based on clinical expertise and research evidence. The disease
progression with time moves vertically from top to bottom.
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management strategies for AS based on clinical expertise and
research evidence. The disease progression with time moves
vertically from top to bottom. This figure emphasises the
importance of non-pharmacological treatments throughout
the course of the disease, early introduction of NSAID
treatment and options for refractory disease, and alternatives
for concomitant peripheral disease.
4. Non-pharmacological treatment of AS should
include patient education and regular exercise.
Individual and group physical therapy should be
considered. Patient associations and self help
groups may be useful
The most recent systematic review of physiotherapy for AS
reviewed six randomised controlled trials (RCTs),26 showing
that home exercise improved function in the short term
compared with no intervention. Supervised exercise pro-
grammes failed to show improvements in pain or function
compared with home exercise, but patient global assessment
was significantly better in patients who underwent group
therapy. Specific physical modalities have not been well
studied. Level Ib evidence supports spa therapy for physical
functioning in patients with AS over 3 months but not
longer, and was shown to be cost effective.27 28
Patient education has been shown to have short term
benefit for function in AS29 in one controlled trial. There are
no studies examining the effect of education on pain.
Education and behavioural therapy have, however, been
shown to be beneficial for other outcomes such as motivation
and anxiety,30 and are cost effective over 12 months.31 Patient
associations and self help groups have not been studied for
their effect on pain or functional outcomes.
5. NSAIDs are recommended as first l ine drug
treatment for patients with AS with pain and
stiffness. In those with increased gastrointestinal
(GI) risk, non-selective NSAIDs plus a
gastroprotective agent, or a selective COX-2
inhibitor could be used
There is convincing evidence (level Ib) that NSAIDs improve
spinal pain, peripheral joint pain, and function over a short
time period (6 weeks). Coxibs are equally effective, showing
large improvements in spinal pain and function in patients
with AS, but peripheral joint pain has not been specifically
examined. Comparative studies of different NSAIDs have not
shown one preparation to be clearly better than the others.
A recent RCT comparing the efficacy of continuous
celecoxib treatment for AS with intermittent ‘‘on demand’’
use suggests that continuous treatment retards radiographic
disease progression at 2 years.32 This is the first study to show
a possible disease modifying effect of continuous treatment,
and warrants further investigation.
The GI toxicity of NSAIDs and coxibs has been elegantly
presented in the recent EULAR recommendations for the
management of hip osteoarthritis.33 In summary, NSAIDs
cause an increased risk of GI bleeding, which is dose
dependent, and can be reduced with the use of gastro-
protective agents. Table 4 shows the relative risks. Coxibs
have a lower risk of serious GI events34 than NSAIDs. The GI
toxicity of NSAIDs in AS may be accounted for by the
recognised risks for NSAID gastropathy (age, concomitant
corticosteroids, etc), suggesting that there is no specific
impact of the disease on GI toxicity from NSAIDs.
The evidence for cardiovascular toxicity related to anti-
inflammatory drugs is rapidly evolving. What was initially
seen as a cardiovascular toxicity signal with rofecoxib35 has
now also been described in large trials of other coxib
preparations in various settings.36–38 Emerging evidence
suggests that non-coxib NSAIDs may possibly share some
of this effect (unpublished data). In general, the choice of
NSAID or coxib should be based on the GI risk profile of the
patient, and should take into account concomitant risk
factors for cardiovascular disease.
6. Analgesics, such as paracetamol and opioids,
might be considered for pain control in patients in
whom NSAIDs are insufficient, contraindicated,
and/or poorly tolerated
Paracetamol and other simple analgesics have not been
prospectively studied in AS. GI toxicity with paracetamol has
been shown to be not significantly higher than placebo in
level 1a studies in other musculoskeletal diseases.39 40
7. Corticosteroid injections directed to the local site
of musculoskeletal inflammation may be considered.
The use of systemic corticosteroids for axial disease
is not supported by evidence
Local inflammation is a key feature of AS, and can occur at
many different musculoskeletal sites, including the axial
joints (most commonly the sacroiliac joints, but can also
occur at the costovertebral and manubriosternal joints),
peripheral joints (usually an asymmetric oligoarthritis, with
predominance of the lower limbs), and enthesitis (plantar
fasciitis, Achilles enthesitis, patellar tendon insertional
enthesitis, involvement near the tibial tuberosity). Intra- or
periarticular corticosteroid injections have been shown to be
effective for the pain of sacroiliitis in small RCTs (level Ib
evidence).41 42 There are no clinical studies evaluating the
efficacy of intra-articular corticosteroid on peripheral arthritis
in AS, or on the use of local corticosteroid injections for the
enthesitis of AS, although the expert group feels that these
can be helpful in selected cases. Potential toxicity including
tendon rupture must be considered.
8. There is no evidence for the efficacy of disease
modifying antirheumatic drugs (DMARDs), including
sulfasalazine and methotrexate, for the treatment of
axial disease. Sulfasalazine may be considered in
patients with peripheral arthrit is
The available level Ia evidence for the efficacy of sulfasalazine
in AS is inconclusive. The most recent meta-analysis43
identified a possible differential response to treatment for
spinal symptoms and for peripheral joint disease. When data
from the individual trials was pooled, there was no
significantly greater effect seen on back pain (ES 22.38,
95% CI 25.78 to 1.03) or physical function (ES 0.20, 95% CI
20.77 to 1.18) with sulfasalazine than with placebo. Long
term trials of sulfasalazine in spondyloarthritis in general
support an effect on peripheral joints but not spinal
inflammation—especially not in patients with longer disease
duration. There is a need for a study of the efficacy of
sulfasalazine and other DMARDs for axial disease in patients
with short disease duration.
In the only extended trial of AS retrieved,44 patients treated
with sulfasalazine over 3 years had significantly fewer
episodes of peripheral joint symptoms than the placebo
group (p,0.05). One observational study failed to show any
effect of sulfasalazine on peripheral enthesitis (level IV
evidence).45 The expert group felt that sulfasalazine was more
relevant for peripheral joint symptoms (mean (SEM)
strength of recommendation 6.53 (0.48)) than for axial
disease (2.80 (0.60)). One RCT was retrieved showing that
sulfasalazine decreases the occurrence of recurrent acute
uveitis in patients with AS.46
Toxicity with sulfasalazine is common but usually mild: GI
symptoms, mucocutaneous manifestations, hepatic enzyme
ASAS/EULAR recommendations for AS 447
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Table 8 ASAS consensus for anti-TNF treatment
Patient selection Specification (definition of the terms)
Diagnosis (a) Patients normally fulfilling modified New York Criteria for definitive AS
(b) Modified New York criteria 1984 (van der Linden et al)
Radiological criterion
- Sacroiliitis, grade >II bilaterally or grade III to IV unilaterally
Clinical criteria (two out of the following three)
- Low back pain and stiffness for .3 months that improves with exercise but is not relieved
by rest
- Limitation of motion of the lumbar spine in both the sagittal and frontal planes
- Limitation of chest expansion relative to normal values correlated for age and sex
Active disease (a) Active disease for >4 weeks
(b) BASDAI >4 (0–10) and an expert* opinion
Treatment failure (a) All patients must have had adequate therapeutic trials of at least two NSAIDs. An
adequate therapeutic trial is defined as:
- Treatment for at least 3 months at maximal recommended or tolerated anti-inflammatory
dose unless contraindicated
- Treatment for ,3 months where treatment was withdrawn because of intolerance,
toxicity, or contraindications
(b) Patients with pure axial manifestations do not have to take DMARDs before anti-TNF
treatment can be started
(c) Patients with symptomatic peripheral arthritis should have an insufficient response to at
least one local corticosteroid injection, if appropriate
(d) Patients with persistent peripheral arthritis must have had a therapeutic trial of
sulfasalazine`
(e) Patients with symptomatic enthesitis for whom appropriate local treatment failed
Contraindication (a) Women who are pregnant or breast feeding; effective contraception must be practised
(b) Active infection
(c) Patients at high risk of infection including:
- Chronic leg ulcer
- Previous tuberculosis (note: please follow local recommendations for prevention or
treatment)
- Septic arthritis of a native joint within the past 12 months
- Sepsis of a prosthetic joint within the past 12 months, or indefinitely if the prosthesis
remains in situ
- Persistent or recurrent chest infections
- Indwelling urinary catheter
(d) History of lupus or multiple sclerosis
(e) Malignancy or premalignancy states excluding:
- Basal cell carcinoma
- Malignancies diagnosed and treated more than 10 years previously (where the
probability of total cure is very high)
Assessment of disease
ASAS core set for
daily practice
(a) Physical function (BASFI or Dougados functional index)
(b) Pain (VAS, past week, spine at night, due to AS and VAS, past week, spine due to AS)
(c) Spinal mobility (chest expansion and modified Schober and occiput to wall distance and
lateral lumbar flexion)
(d) Patient’s global assessment (VAS, past week)
(e) Stiffness (duration of morning stiffness, spine, past week)
(f) Peripheral joints and entheses (number of swollen joints (44 joint count), enthesitis score
such as developed in Maastricht, Berlin, or San Francisco)
(g) Acute phase reactants (ESR or CRP)
(h) Fatigue (VAS)
BASDAI (a) VAS overall level of fatigue/tiredness past week
(b) VAS overall level of AS neck, back, or hip pain past week
(c) VAS overall level of pain/swelling in joints other than neck, back, or hips past week
(d) VAS overall discomfort from any areas tender to touch or pressure past week
(e) VAS overall level of morning stiffness from time of awakening past week
(f) Duration and intensity (VAS) of morning stiffness from time of awakening (up to
120 minutes)
Assessment of response
Responder criteria BASDAI: 50% relative change or absolute change of 20 mm (on a scale of 0–100) and
expert opinion in favour of continuation
Time of evaluation Between 6 and 12 weeks
*The expert is a physician, usually a rheumatologist, with expertise in inflammatory back pain and the use of
biological agents. Expert should be locally defined; an expert opinion comprises both clinical features (history and
examination) and serum acute phase reactant levels and/or imaging results, such as radiographs demonstrating
rapid progression or MRI scans indicating continuing inflammation; `sulfasalazine: treatment for at least 4 months
at standard target dose or maximally tolerated dose unless contraindicated or not tolerated. Treatment for
,4 months, where treatment was withdrawn because of intolerance or toxicity or contraindicated.
VAS, visual analogue scale; all VAS can be replaced by a numerical rating scale (NRS).
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abnormalities, and haematological abnormalities have been
described (table 4).
There has been no meta-analysis of methotrexate for AS,
with the only systematic review retrieved unable to combine
results.47 Therefore the best evidence from the literature is
level Ib, with three RCTs identified.48–50 Pooling results where
possible did not show a significant effect of methotrexate on
spinal pain or function. The only study to report separate
outcomes for peripheral joint disease49 did not identify
significant benefit with treatment.
The most commonly reported side effects occurring with
methotrexate treatment include nausea and hepatic abnorm-
alities (table 4). Folate is effective in preventing GI symptoms
and mucocutaneous adverse events.51
There is little evidence to support the use of other DMARDs
commonly used in other inflammatory arthritides in AS
(table 3). There is level III evidence for a beneficial effect of
intravenous pamidronate on both axial pain and function,52
but the study was not powered to assess an effect on
peripheral joint disease. Further RCTs are needed to answer
this question. Side effects include transient post-infusional
arthralgias and myalgias52–54 and an acute phase response
with lymphopenia and raised C reactive protein.55 Open trials
suggest a beneficial effect for thalidomide on spinal
disease,56 57 but toxicity is substantial, and when combined
with the well recognised association of thalidomide with
severe birth defects and potentially irreversible peripheral
neuropathies, the expert opinion of the group was that the
toxicity profile of thalidomide outweighed any potential
therapeutic benefit.
9. Anti-TNF treatment should be given to patients
with persistently high disease activity despite
conventional treatments according to the ASAS
recommendations. There is no evidence to support
the obligatory use of DMARDs before, or
concomitant with, anti-TNF treatment in patients
with axial disease
RCTs (level Ib evidence) support the use of the TNF inhibitors
etanercept58–61 and infliximab62 63 for spinal pain, function,
and peripheral joint disease. Effect sizes are large (table 3),
and the number needed to treat to achieve an ASAS20
response is low. Adalimumab, the most recent TNF antago-
nist to become available for treatment in rheumatic diseases,
has also been shown to be effective in a level III study.64
The onset of clinical effect with TNF blockers is rapid,59 and
therapeutic effect persists for up to 3 years with continuing
treatment.65–68 Stopping treatment results in a high propor-
tion of patients with clinical relapse.69 Although adding
methotrexate to infliximab treatment in rheumatoid arthritis
improves clinical outcome70 and reduces side effects,71 there
has been no evidence to support any additional benefit with
concomitant methotrexate use in AS.72 The ASAS group has
published a comprehensive, evidence based consensus state-
ment for the initiation of anti-TNF treatment in AS73 74
(table 8) to identify appropriate therapeutic candidates.
Toxicity with anti-TNF treatment includes injection site
reactions with subcutaneous injections (etanercept and
adalimumab) and uncommon infusion reactions with intra-
venous infliximab. Open trials have shown treatment to be
associated with increased risk of infection75 76—in particular,
tuberculosis.77 78 Screening for Mycobacterium tuberculosis is
now a standard prerequisite for anti-TNF treatment.
Demyelinating disease,79 lupus-like syndromes,80–82 and wor-
sening of pre-existing congestive heart failure83–85 have also
been reported in case series, although precise incidences are
not known.
Although significantly more expensive than traditional AS
treatments, the large improvements in pain and function
with TNF blocker treatment may well outweigh the high
costs in a formal cost-benefit analysis,86 87 projecting over
30 years that such treatments are even more cost effective
when function and therefore productivity are preserved.
Further economic evaluation is required to confirm this
projection.
There is insufficient evidence available at present to make a
definite statement on the role of interleukin 1 antagonists in
AS.
10. Total hip arthroplasty should be considered in
patients with refractory pain or disabili ty and
radiographic evidence of structural damage,
independent of age. Spinal surgery—for example,
corrective osteotomy and stabilisation procedures,
may be of value in selected patients
The best evidence for total hip arthroplasty (THA) is level IV,
with prospective cohort studies in patients with AS showing
good pain relief and functional improvement with surgery.88
Although age and sex predict revision rate in THA,89 revision
rates in AS are not unduly high. Rates of heterotopic bone
formation and re-ankylosis after THA are not increased in
patients with AS.90–93 Collective clinical experience is that
heterotopic ossification is no more common in the AS
population, dependent on surgical technique, and this is
likely to be affected by NSAID use in AS, and the routine
practice of preoperative NSAID prophylaxis. The administra-
tion of NSAIDs on the evening before surgery (conventional
practice) does not have an effect on perioperative bleeding or
complication rate. The expert group agreed that NSAID
treatment does not need to be discontinued for THA surgery.
The difference in long term durability or complications
between cemented and non-cemented hip prostheses is not
large, but THA in younger patients generally uses non-
cemented prostheses, as later revisions are technically easier
(related to loss of bone structure). There are no comparative
studies on this item in patients with AS.
Spinal surgery is performed for a number of indications in
AS, including disabling kyphosis, loss of horizontal vision
without compensation, painful spinal pseudarthrosis or
Andersson lesion, pain and/or segmental instability of spinal
fractures, and less commonly, neurological complications
such as spinal stenosis, myelopathy, and rarely, cauda equina
syndrome. Closing wedge lumbar osteotomy for fixed
kyphotic deformity causing major disability can give excellent
functional results by restoring balance and horizontal
vision.94 Instrumentation failure has been a problem with
polysegmental wedge osteotomies,95 but permanent neurolo-
gical complications are rare. Fusion procedures should be
considered in patients with segmental instability as a result
of spinal pseudarthrosis or Andersson lesion, and in cases of
instability or intractable pain due to spinal fracture.
Corrective surgery of the cervical spine should be reserved
for those patients with AS with specific indications, and
considered for patients individually.
DISCUSSION
This is the first time that international recommendations for
the management of AS have been developed, and it is also the
first official collaboration of ASAS and EULAR. Recently,
ASAS has successfully collaborated with the FDA and the
North American patient organisation ‘‘Spondylitis
Association of America’’ to produce recommendations for
clinical trials.96
The major driving forces for this current project were (a)
the rapid developments seen in available treatments for AS
over recent years; (b) the dedicated aim of ASAS to provide
valuable assessment tools for AS; and (c) the standardised
approach by EULAR to producing recommendations for
ASAS/EULAR recommendations for AS 449
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common rheumatic diseases. Given the almost dramatic
history of successful approvals of anti-TNF agents in the past
3 years—which is still continuing—it is becoming increas-
ingly important to assess relative benefits of the different
treatments and to distinguish which are the most efficacious
in particular patient settings. For this reason the ASAS and
EULAR took on the challenge of developing evidence based
recommendations for the management of AS.
The methods used to develop the recommendations were
based on the standardised operating procedures published by
EULAR,6 created to assist the promotion of high quality and
comparability between studies of the management of
musculoskeletal diseases. Recommendations for the manage-
ment of knee osteoarthritis (OA)97 and for hip OA33 have
already been developed using these methods. Evidence
hierarchy was used as the primary means of describing
how strong or convincing the available evidence might be.
This method considers the problem that poorly conducted or
reported trials may be included, falsely increasing the level of
evidence. In those cases where a particular study was felt to
be of poor quality, this was disclosed to the expert group and
included in the discussion of the literature.
The literature supported 10 of the treatments identified for
AS with level III evidence or higher, and supported negative
evidence for four modalities. Six modalities had limited level
IV evidence. It is important to emphasise that this assessment
focused on an effect on pain or function, not on other
outcomes which might be important and relevant to
particular treatments, but were not used as primary outcomes
in this exercise.
The group decided at the outset of this project to
concentrate on the effect of treatment on pain and function,
two cardinal clinical features of AS which are commonly
impaired and impart significant disability and distress to
patients. The recently described ASAS20 composite measure
of treatment response, comprising pain, function, spinal
stiffness, and patient global assessment,98 99 was also
included as a primary outcome measure where available.
This is a relatively new outcome measure, with only the anti-
TNF studies and the more recent NSAID trials reporting this.
The expert committee emphasises that this in no way
suggests that pain and function are the only important
outcomes in AS; often the most important measure of
therapeutic effect is very treatment-specific—for example,
patient satisfaction, compliance, confidence, and coping.
Thus, a broader approach is usually required in individual
patient care.
The use of an evidence hierarchy to reflect the strength of
support for a treatment is intrinsically flawed when
considering such interventions as surgery. There can only
be level III evidence to support the use of THA in AS owing to
the technical, as well as ethical, impossibilities of performing
a randomised, double blind controlled trial for a surgical
procedure. In this case expert opinion is a valuable addition
to the available literature. Similarly, in instances where no
studies have been conducted to answer a specific question,
the absence of clinical trials means that expert opinion (level
IV evidence) is the best available evidence.
A new method for measuring the strength of a recom-
mendation was recently proposed in the EULAR recommen-
dations for hip OA,100 combining available research evidence
with expert opinion to give a single index, measured by a
100 mm visual analogue scale (VAS) or an ordinal scale. The
measure reflects a combination of literature evidence, clinical
experience, and patient perceived acceptance and tolerability,
as rated by the experts. We have used this approach to
quantify the overall support the experts gave each of the
treatment modalities, with an NRS in place of the VAS for the
final strength of recommendation for each modality. Zhang
et al did not show good correlation between expert opinion
and the research evidence.100 This was not surprising, as in
many situations with low level evidence there is still strong
expert opinion owing to clinical experience. Therefore the two
approaches should complement each other, but may not
necessarily agree.
The GRADE group has developed a multidimensional
system to assess the grade of evidence,101–103 which is slightly
more extensive than the concept of level of evidence used for
the AS recommendations. It incorporates the study design,
methodological quality, consistency of results between
studies, applicability of evidence to the population under
consideration, and missing data, in order to assess the overall
quality of the result, and the confidence that the result of the
research evidence is correct. Although a very comprehensive
method of assessing treatment modalities, the GRADE
system is complicated and difficult to implement in extensive
therapeutic reviews such as that carried out here. The
additional problems examined by GRADE were incorporated
into the expert group discussions on each recommendation
point where applicable.
Taken together, the expert group agreed on 10 major
recommendations for the management of AS on the basis of
the best available evidence. This is considered an important
starting point to provide guidance for monitoring and
treatment of patients with AS. It is important to realise that
these are recommendations not guidelines; the lengthy
discussions of the expert group for each of the 10 final
points indicate that the final proposals were a synthesis of
quite marked variations in opinion. The recommendations
reflect expert opinion based on the current research evidence.
They will be updated regularly, to keep abreast of new
developments in the treatment of AS.
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